"Bergeron and Chan have done a marvelous job integrating many different perspectives to give the reader a coherent road map of the biotech industry for the next decade. This powerful book is anchored by numerous relevant examples that create a framework which any life sciences professional needs to understand. Of particular note is the compelling assessment of the IT industry and its impact on the life sciences as these industries converge."--Michael A. Greeley, Managing General Partner, IDG Ventures.
An in-depth examination of the growth and financing of the biotechnology industry worldwide
Biotech Industry: A Global, Economic, and Financing Overview provides a thorough look at the current state of the biotechnology industry, including where major research is being conducted, where it's being applied, and where money and intellectual capital are flowing.
Written by a renowned business columnist and an entrepreneurial scientist in the biotech area, this unique book gives Eos and other senior-level managers an understanding of Asia's pivotal role in the worldwide success of biotechnology commercialization, as well as insight into the biotech market over the next decade.
Preface xi
Acknowledgments xvii
CHAPTER 1
Overview 1
CHAPTER 2
Pharmaceuticals 43
CHAPTER 3
Medicine and Agriculture 77
CHAPTER 4
Computing, Biomaterials, and the Military 105
CHAPTER 5
Infrastructure 142
CHAPTER 6
Financing 175
CHAPTER 7
Regional Analysis 217
CHAPTER 8
Outlook 295
Appendix 319
Glossary 329
Sources and Further Reading 337
Index 347
John P. Glaser
Vice President and Chief Information Officer
Partners Healthcare System, Inc.
"Bergeron and Chan have done a marvelous job integrating many different perspectives to give the reader a coherent road map of the biotech industry for the next decade. This powerful book is anchored by numerous relevant examples that create a framework which any life sciences professional needs to understand. Of particular note is the compelling assessment of the IT industry and its impact on the life sciences as these industries converge."
Michael A. Greeley
Managing General Partner
IDG Ventures
An in-depth examination of the growth and financing of the biotechnology industry worldwide
Biotech Industry: A Global, Economic, and Financing Overview provides a thorough look at the current state of the biotechnology industry, including where major research is being conducted, where its being applied, and where money and intellectual capital are flowing.
Written by a renowned business columnist and an entrepreneurial scientist in the biotech area, this unique book gives CEOs and other senior-level managers an understanding of Asias pivotal role in the worldwide success of biotechnology commercialization, as well as insight into the biotech market over the next decade.
“Bergeron and Chan have done a marvelous job integrating many different perspectives to give the reader a coherent road map of the biotech industry for the next decade. This powerful book is anchored by numerous relevant examples that create a framework which any life sciences professional needs to understand. Of particular note is the compelling assessment of the IT industry and its impact on the life sciences as these industries converge.”—Michael A. Greeley, Managing General Partner, IDG Ventures.
Looking beyond the hype of get-rich-quick investment schemes, Biotech Industry: A Global, Economic, and Financing Overview provides CEOs and other upper-level managers with a comprehensive, critical analysis of the biotechnology business from a uniquely Pan-Asia perspective.
With a cutting-edge focus for forward-thinking business leaders, this reliable reference offers a clear vision of the global biotech market through 2010, including which regions and corporations are best positioned to dominate the market.
Through timely coverage, this relevant volume gives readers an appreciation for the unique political and socioeconomic landscape within which academic and entrepreneurial biotechnology laboratories operate. Coverage includes a focus on the financial, technological, and infrastructure-building activities underway (primarily in Asia) that are reminiscent of the infrastructure building in the semiconductor industry.
Because the biotechnology field crosses so many traditional boundaries, successful CEOs and other senior-level corporate executives in the industry need a guide to both business principles and the biology, physics, and information technologies related to their companys products and services. The global market also demands successful executives be skilled in public relations and managing the press with due respect to social, political, and religious concerns surrounding biotechnology research.
Private and government-sponsored laboratories in Asia are scrambling to develop many of the core technologies that will drive biotechnology developments in the United States, European Union, Australia, and elsewhere. Biotech Industry: A Global, Economic, and Financing Overview offers valuable insight into where this major research is being conducted, where its being applied, and where money and intellectual capital are flowing.
Produktdetaljer
Biografisk notat
Bryan Bergeron is the author of twelve books, including Essentials of Shared Services, Essentials of Knowledge Management, and Business Expectations: Are You Using Technology to its Fullest? (all published by Wiley). He also serves as editor in chief of e.MD and technical editor of Postgraduate Medicine, is on the editorial boards of Healthcare Informatics and Perspectives in Biology and Medicine, and is a columnist for WebMD. He teaches technology and business courses at Harvard Medical School and MIT.
Paul Chan is a columnist specializing in technology finance, value-based management, and private equity for Asia's leading business newspaper, Business Times, where he currently heads the new media unit. He has had a long and successful career as an equity strategist and management consultant, and he has advised a gamut of global institutional investors. He also has directed equity research at some of Asia's largest brokerage houses.